Sima Porten, MD, MPH

Title(s)Associate Professor, Urology
SchoolSchool of Medicine
Address550 16th. Street, #6207
San Francisco CA 94158
Phone415-353-7171
Pronounsshe/her/hers
ORCID ORCID Icon0000-0002-3948-4968 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, San Francisco, CA2017Diversity, Equity, and Inclusion Champion Training

    Collapse Overview 
    Collapse Overview
    Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer.

    Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer.

    Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer.

    Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology.

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Academic Senate

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains. Oncologist. 2024 Aug 05; 29(8):e1094-e1097. Zhu X, Chan E, Turski ML, Mendez CE, Hsu SC, Kumar V, Shipp C, Jindal T, Chang K, Onodera C, Devine WP, Grenert JP, Stohr BA, Ding CC, Stachler MD, Quigley DA, Feng FY, Chu CE, Porten SP, Chou J, Friedlander TW, Koshkin VS. PMID: 38908022; PMCID: PMC11299940.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO Precis Oncol. 2024 Jun; 8:e2300362. Satyal U, Valentine H, Liu D, Slifker M, Lallas CD, Trabulsi EJ, Bukavina L, Szeto L, Hoffman-Censits JH, Mouw KW, Faltas BM, Grivas P, Ibragimova I, Porten SP, Van Allen EM, Geynisman DM, Parker DC, O'Neill JP, Drevik J, Christianson SS, Ginzburg S, Correa AF, Uzzo RG, Ross EA, Zibelman MR, Ghatalia P, Plimack ER, Kutikov A, Abbosh PH. PMID: 38865671.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    3. "I think my vagina is still there?": Women's perspectives on sexual function and dysfunction following radical cystectomy for bladder cancer, a qualitative study. J Sex Med. 2024 Apr 30; 21(5):464-470. Ceasar RC, Ladi-Seyedian SS, Escobar D, Han J, Koh K, Porten S, Chu C, Gould EE, Bhanvadia S. PMID: 38491395.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units. Urology. 2024 Apr 20. Briggs LG, Labban M, Ye J, Herzog P, Jones AN, Nguyen DD, Wallis CJD, Wolter C, Porten S, Trinh QD. PMID: 38648950.
      View in: PubMed   Mentions:    Fields:    
    5. Association of household net worth with healthcare costs after radical cystectomy using real-world data. Cancer Med. 2024 Apr; 13(7):e7116. Washington SL, Lonergan PE, Odisho AY, Meng MV, Porten SP. PMID: 38553953; PMCID: PMC10980929.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    6. Evaluation of URO17® to improve non-invasive detection of bladder cancer. Urol Oncol. 2024 Jun; 42(6):176.e21-176.e28. Porten SP, Wang EY, Vohra P, Carroll PR, Jahanfard S, Kim NW. PMID: 38553264.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    7. Racial Differences in the Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry. Cancers (Basel). 2024 Mar 24; 16(7). Ladi-Seyedian SS, Ghoreifi A, Konety B, Pohar K, Holzbeierlein JM, Taylor J, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S. PMID: 38610946; PMCID: PMC11011163.
      View in: PubMed   Mentions:
    8. Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer. J Nucl Med. 2024 Feb 01; 65(2):199-205. Koshkin VS, Kumar V, Kline B, Escobar D, Aslam M, Cooperberg MR, Aggarwal RR, de Kouchkovsky I, Chou J, Meng MV, Friedlander T, Porten S, Hope TA. PMID: 38212070.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    9. Standardization of the evaluation and surveillance of patients with BCG unresponsive high grade non-muscle invasive bladder cancer clinical trials. Urol Oncol. 2024 Aug; 42(8):223-228. Lotan Y, Agarwal P, Black P, Dickstein R, Kamat AM, Lee B, Narayan VM, Porten S, Psutka SP, Smith AK, Svatek RS, Williams SB, Woldu S. PMID: 38307803.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Commentary on Novitas LCD. Bladder Cancer. 2023; 9(4):305-312. Lotan Y, Barocas DA, Chang SS, Daneshmand S, Konety B, Meeks JJ, Porten S, Raman JD, Rosser CJ, Scarpato KR, Sexton WJ, Sfakianos JP, Shore ND, Svatek RS. PMID: 38994243; PMCID: PMC11165914.
      View in: PubMed   Mentions:
    11. Wake-Up Call to Address Sleep Health in Non-Muscle Invasive Bladder Cancer: Underappreciated Contributor to Poor Quality of Life. Bladder Cancer. 2023; 9(4):323-326. Wang EY, Armas-Phan M, Meng MV, Loeb S, Kenfield SA, Porten SP. PMID: 38174125; PMCID: PMC10759800.
      View in: PubMed   Mentions:
    12. Interruptions in bladder cancer care during the COVID-19 public health emergency. Urol Oncol. 2024 04; 42(4):116.e17-116.e21. Gore JL, Follmer K, Reynolds J, Nash M, Anderson CB, Catto JWF, Chamie K, Daneshmand S, Dickstein R, Garg T, Gilbert SM, Guzzo TJ, Kamat AM, Kates MR, Lane BR, Lotan Y, Mansour AM, Master VA, Montgomery JS, Morris DS, Nepple KG, O'Neil BB, Patel S, Pohar K, Porten SP, Riggs SB, Sankin A, Scarpato KR, Shore ND, Steinberg GD, Strope SA, Taylor JM, Comstock BA, Kessler LG, Wolff EM, Smith AB. PMID: 38087711.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    13. Protocol of the Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) study: a pragmatic, prospective multicenter observational cohort study of recurrent high-grade non-muscle invasive bladder cancer. BMC Cancer. 2023 Nov 18; 23(1):1127. Gore JL, Wolff EM, Comstock BA, Follmer KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, Porten SP, Steinberg GD, Chang SS, Gilbert SM, Kessler LG, Smith AB, CISTO Collaborative. PMID: 37980511; PMCID: PMC10657633.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer. Bladder Cancer. 2023; 9(3):271-286. Chang E, Hahn NM, Lerner SP, Fallah J, Agrawal S, Kamat AM, Bhatnagar V, Svatek RS, Jaigirdar AA, Bross P, Shore N, Kates M, Sachse K, Brewer JR, O'Donnell MA, Steinberg GD, Viviano CJ, Bloomquist E, Ribal MJ, Galsky MD, Oliver R, Black PC, Al-Ahmadie H, Brothers K, Pohar K, Dinney CP, Feng Z, Downs TM, Porten SP, Smith AB, Bangs R, Psutka SP, Agarwal N, Amiri-Kordestani L, Suzman DL, Pazdur R, Kluetz PG, Weinstock C. PMID: 38993184; PMCID: PMC11181701.
      View in: PubMed   Mentions: 1  
    15. Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544. Black PC, Tangen CM, Singh P, McConkey DJ, Lucia MS, Lowrance WT, Koshkin VS, Stratton KL, Bivalacqua TJ, Kassouf W, Porten SP, Bangs R, Plets M, Thompson IM, Lerner SP. PMID: 37596191; PMCID: PMC10869634.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCTClinical Trials
    16. Background and Update for ECOG-ACRIN EA8212: A Randomized Phase 3 Trial of Intravesical Bacillus Calmette-Guérin (BCG) Versus Intravesical Docetaxel and Gemcitabine Treatment in BCG-naïve High-grade Non-muscle-invasive Bladder Cancer (BRIDGE). Eur Urol Focus. 2023 07; 9(4):561-563. Kates M, Chu X, Hahn N, Pietzak E, Smith A, Shevrin DH, Crispen P, Williams SB, Daneshmand S, Packiam VT, Porten S, Westerman ME, Wagner LI, Carducci M. PMID: 37422371; PMCID: PMC10515442.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    17. Readmissions trends following radical cystectomy for bladder cancer unchanged in the era of enhanced recovery after surgery (ERAS) protocols. Urol Oncol. 2023 08; 41(8):355.e19-355.e28. Chappidi MR, Escobar D, Meng MV, Washington SL, Porten SP. PMID: 37258373.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin. Clin Genitourin Cancer. 2023 10; 21(5):e394-e404. Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal R, Small EJ, Fong L, Chou J, Friedlander T, de Kouchkovsky I, Koshkin VS. PMID: 37316414.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    19. Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer. Front Oncol. 2023; 13:1161089. Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou J, Friedlander T, Koshkin VS. PMID: 37091148; PMCID: PMC10113661.
      View in: PubMed   Mentions: 3  
    20. Cxbladder Monitor testing to reduce cystoscopy frequency in patients with bladder cancer. Urol Oncol. 2023 07; 41(7):326.e1-326.e8. Li KD, Chu CE, Patel M, Meng MV, Morgan TM, Porten SP. PMID: 36868882.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    21. Is a restaging TURBT necessary in high-risk NMIBC if the initial TURBT was performed with blue light? Urol Oncol. 2023 02; 41(2):109.e9-109.e14. Alsyouf M, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy with Cysview Registry Group. PMID: 36435710.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    22. Epidemiology, Screening, and Prevention of Bladder Cancer. Eur Urol Oncol. 2022 12; 5(6):628-639. Lobo N, Afferi L, Moschini M, Mostafid H, Porten S, Psutka SP, Gupta S, Smith AB, Williams SB, Lotan Y. PMID: 36333236.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    23. Sex-specific Augmentation of Treatment Responses in Bladder Cancer. Eur Urol Open Sci. 2022 Dec; 46:43-44. Chang K, Porten SP. PMID: 36325367; PMCID: PMC9618772.
      View in: PubMed   Mentions:
    24. Which Biomarkers are Useful in the Management of Muscle-invasive Bladder Cancer in 2022? Eur Urol Focus. 2022 07; 8(4):901-903. Szymaniak J, Porten SP. PMID: 36058810.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Origins and Timing of Emerging Lesions in Advanced Renal Cell Carcinoma. Mol Cancer Res. 2022 06 03; 20(6):909-922. Wallace A, Porten SP, Lo AA, Oreper D, Lounsbury N, Havnar C, Pechuan-Jorge X, Zill OA, Meng MV. PMID: 35297992; PMCID: PMC9381131.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Use of a Convex Pouching System in the Postoperative Period: A National Consensus. J Wound Ostomy Continence Nurs. 2022 May-Jun 01; 49(3):240-246. Colwell JC, Stoia Davis J, Emodi K, Fellows J, Mahoney M, McDade B, Porten S, Raskin E, Sims T, Norman H, Kelly MT, Gray M. PMID: 35523239; PMCID: PMC9093727.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    27. Survey Results on Use of a Convex Pouching System in the Postoperative Period. J Wound Ostomy Continence Nurs. 2022 May-Jun 01; 49(3):247-250. Stoia-Davis J, Colwell JC, Emodi K, Fellows J, Mahoney M, McDade B, Porten SP, Raskin ER, Norman HS, Kelly MT, Sims T. PMID: 35523240; PMCID: PMC9093726.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    28. Holistic Characterization of Tumor Monocyte-to-Macrophage Differentiation Integrates Distinct Immune Phenotypes in Kidney Cancer. Cancer Immunol Res. 2022 04 01; 10(4):403-419. Mujal AM, Combes AJ, Rao AA, Binnewies M, Samad B, Tsui J, Boissonnas A, Pollack JL, Argüello RJ, Meng MV, Porten SP, Ruhland MK, Barry KC, Chan V, Krummel MF. PMID: 35181780; PMCID: PMC8982148.
      View in: PubMed   Mentions: 14     Fields:    Translation:AnimalsCells
    29. Systematic review of sleep and sleep disorders among prostate cancer patients and caregivers: a call to action for using validated sleep assessments during prostate cancer care. Sleep Med. 2022 06; 94:38-53. Robbins R, Cole R, Ejikeme C, Orstad SL, Porten S, Salter CA, Sanchez Nolasco T, Vieira D, Loeb S. PMID: 35489117; PMCID: PMC9277625.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    30. APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer. Front Oncol. 2022; 12:816706. Natesan D, Zhang L, Martell HJ, Jindal T, Devine P, Stohr B, Espinosa-Mendez C, Grenert J, Van Ziffle J, Joseph N, Umetsu S, Onodera C, Turski M, Chan E, Desai A, Aggarwal R, Wong A, Porten S, Chou J, Friedlander T, Fong L, Small EJ, Sweet-Cordero A, Koshkin VS. PMID: 35321431; PMCID: PMC8935010.
      View in: PubMed   Mentions: 5  
    31. TROP2 Expression Across Molecular Subtypes of Urothelial Carcinoma and Enfortumab Vedotin-resistant Cells. Eur Urol Oncol. 2022 12; 5(6):714-718. Chou J, Trepka K, Sjöström M, Egusa EA, Chu CE, Zhu J, Chan E, Gibb EA, Badura ML, Contreras-Sanz A, Stohr BA, Meng MV, Pruthi RS, Lotan Y, Black PC, Porten SP, Koshkin VS, Friedlander TW, Feng FY. PMID: 35216942; PMCID: PMC10262920.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    32. Clinical Utility of Rigid Blue Light Cystoscopy: Results from a Post Procedure User Survey in a Prospective Multicenter Registry. Urol Pract. 2022 01; 9(1):94-100. Stout TE, Regmi SK, Daneshmand S, Porten SP, Pohar KS, Konety BR. PMID: 37145566.
      View in: PubMed   Mentions:    Fields:    
    33. Role of blue-light cystoscopy in detecting invasive bladder tumours: data from a multi-institutional registry. BJU Int. 2022 07; 130(1):62-67. Ahmadi H, Ladi-Seyedian SS, Konety B, Pohar K, Holzbeierlein JM, Kates M, Willard B, Taylor JM, Liao JC, Kaimakliotis HZ, Porten SP, Steinberg GD, Tyson MD, Lotan Y, Daneshmand S, Blue Light Cystoscopy with Cysview Registry Group. PMID: 34637596.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. Utility of Blue Light Cystoscopy for Post-bacillus Calmette-Guérin Bladder Cancer Recurrence Detection: Implications for Clinical Trial Recruitment and Study Comparisons. J Urol. 2022 Mar; 207(3):534-540. Chappidi MR, Yang H, Meng MV, Bivalacqua TJ, Daneshmand S, Holzbeierlein JM, Kaimakliotis HZ, Konety B, Liao JC, Pohar K, Steinberg GD, Taylor JM, Tyson MD, Willard B, Lotan Y, Porten SP, Kates M. PMID: 34694916.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    35. Urothelial Carcinoma and Prostate-specific Membrane Antigen: Cellular, Imaging, and Prognostic Implications. Eur Urol Focus. 2022 09; 8(5):1256-1269. Tariq A, McCart Reed AE, Morton A, Porten S, Vela I, Williams ED, Yaxley JW, Black PC, Roberts MJ. PMID: 34429271.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    36. The Diagnostic Performance of Cxbladder Resolve, Alone and in Combination with Other Cxbladder Tests, in the Identification and Priority Evaluation of Patients at Risk for Urothelial Carcinoma. J Urol. 2021 12; 206(6):1380-1389. Raman JD, Kavalieris L, Konety B, Porten S, Daneshmand S, Lotan Y, Loo R. PMID: 34348469; PMCID: PMC8584223.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    37. Applicant perceptions of virtual interviews for society of urologic oncology fellowships during the COVID-19 pandemic. Urol Oncol. 2023 02; 41(2):65-68. Gore JL, Porten SP, Montgomery JS, Hamilton RJ, Meng MV, Sexton WJ, Psutka SP. PMID: 34247905; PMCID: PMC9760099.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansPHPublic Health
    38. Evaluation of the Cancer of Bladder Risk Assessment (COBRA) Score in the Cancer Genome Atlas (TCGA) Bladder Cancer Cohort. Urology. 2021 10; 156:104-109. Chappidi MR, Welty C, Choi W, Meng MV, Porten SP. PMID: 34118229.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    39. Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res. 2021 09 15; 27(18):5123-5130. Chu CE, Sjöström M, Egusa EA, Gibb EA, Badura ML, Zhu J, Koshkin VS, Stohr BA, Meng MV, Pruthi RS, Friedlander TW, Lotan Y, Black PC, Porten SP, Feng FY, Chou J. PMID: 34108177; PMCID: PMC8634828.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCells
    40. Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy. Urol Oncol. 2021 12; 39(12):833.e19-833.e26. Matulewicz RS, Ravvaz K, Weissert JA, Porten S, Steinberg GD, Blue Light Cystoscopy with Cysview Registry Group. PMID: 34053856.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    41. TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor. J Immunother Cancer. 2021 05; 9(5). de Kouchkovsky I, Zhang L, Philip EJ, Wright F, Kim DM, Natesan D, Kwon D, Ho H, Ho S, Chan E, Porten SP, Wong AC, Desai A, Huang FW, Chou J, Oh DY, Pruthi RS, Fong L, Small EJ, Friedlander TW, Koshkin VS. PMID: 33980590; PMCID: PMC8118032.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    42. Research highlights of the 2020 society of urologic oncology young urologic oncologists' program. Urol Oncol. 2021 08; 39(8):452-454. Klaassen Z, Scarpato KR, Ristau BT, Stratton KL, Porten SP, Smaldone MC, Chapin BF, Psutka SP. PMID: 33858748; PMCID: PMC9647056.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    43. Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. Eur Urol. 2021 06; 79(6):717-721. Chu CE, Alshalalfa M, Sjöström M, Zhao SG, Liu Y, Chou J, Herlemann A, Mahal B, Kishan AU, Spratt DE, Cooperberg M, Small E, Wong A, Porten S, Hope TA, Ross AE, Davicioni E, Nguyen P, Karnes RJ, Carroll PR, Schaeffer E, Feng FY. PMID: 33840559.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    44. Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. Urology. 2021 Mar; 149:168-173. Chu CE, Law L, Zuniga K, Lin TK, Tsourounis C, Rodriguez-Monguio R, Lazar A, Washington SL, Cooperberg MR, Greene KL, Carroll PR, Pruthi RS, Meng MV, Chen LL, Porten SP. PMID: 33278460.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Women in Leadership in Urology: The Case for Increasing Diversity and Equity. Urology. 2021 04; 150:16-24. Chyu J, Peters CE, Nicholson TM, Dai JC, Taylor J, Garg T, Smith AB, Porten SP, Greene K, Browning N, Harris E, Sutherland SE, Psutka SP. PMID: 32961220.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    46. Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. Cancer Med. 2020 11; 9(22):8310-8317. Washington SL, Gregorich SE, Meng MV, Suskind AM, Porten SP. PMID: 32869516; PMCID: PMC7666728.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    47. Assessing Contemporary Trends in Female Speakership within Urologic Oncology. Urology. 2021 04; 150:41-46. Talwar R, Bernstein A, Jones A, Crook J, Apolo AB, Taylor JM, Burke LM, Plimack ER, Porten SP, Greene KL, Psutka SP, Smith AB. PMID: 32798517; PMCID: PMC9257999.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    48. Bladder tumor recurrence after urothelial carcinoma of the upper urinary tract. Transl Androl Urol. 2020 Aug; 9(4):1891-1896. Lonergan PE, Porten SP. PMID: 32944553; PMCID: PMC7475654.
      View in: PubMed   Mentions: 6  
    49. Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. World J Urol. 2021 Jun; 39(6):1911-1916. de la Calle CM, Washington SL, Lonergan PE, Meng MV, Porten SP. PMID: 32737581.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    50. Correction to: A comparison of stage-specific all-cause mortality between testicular sex cordstromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 07 17; 20(1):103. Zuniga KB, Washington SL, Porten SP, Meng MV. PMID: 32680507; PMCID: PMC7368670.
      View in: PubMed   Mentions:    Fields:    
    51. Using provider-focused education toolkits can aid enhanced recovery programs to further reduce patient exposure to opioids. Perioper Med (Lond). 2020; 9:21. Sarin A, Lancaster E, Chen LL, Porten S, Chen LM, Lager J, Wick E. PMID: 32670568; PMCID: PMC7346381.
      View in: PubMed   Mentions:
    52. Intratumoral CD4+ T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer. Cell. 2020 06 25; 181(7):1612-1625.e13. Oh DY, Kwek SS, Raju SS, Li T, McCarthy E, Chow E, Aran D, Ilano A, Pai CS, Rancan C, Allaire K, Burra A, Sun Y, Spitzer MH, Mangul S, Porten S, Meng MV, Friedlander TW, Ye CJ, Fong L. PMID: 32497499; PMCID: PMC7321885.
      View in: PubMed   Mentions: 284     Fields:    Translation:HumansCells
    53. Reply by Authors. J Urol. 2020 08; 204(2):246. de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA. PMID: 32459975.
      View in: PubMed   Mentions:    Fields:    
    54. A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database. BMC Urol. 2020 Apr 17; 20(1):40. Zuniga KB, Washington SL, Porten SP, Meng MV. PMID: 32303266; PMCID: PMC7164279.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    55. Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. Bladder Cancer. 2020; 6(1):9-23. Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA. PMID: 34095407; PMCID: PMC8174672.
      View in: PubMed   Mentions: 6  
    56. Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. Eur Urol Oncol. 2020 08; 3(4):420-423. de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP. PMID: 32205136.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    57. TCF21 Promotes Luminal-Like Differentiation and Suppresses Metastasis in Bladder Cancer. Mol Cancer Res. 2020 06; 18(6):811-821. Mokkapati S, Porten SP, Narayan VM, Lim AH, Jayaratna IS, Roth B, Cheng T, Navai N, Wszolek M, Melquist J, Manyam G, Choi W, Broom B, Pretzsch S, Czerniak B, McConkey DJ, Dinney CPN. PMID: 32122956.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    58. A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Up Staging. J Urol. 2020 08; 204(2):239-246. de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA. PMID: 32074006.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    59. An evaluation of the real world use and clinical utility of the Cxbladder Monitor assay in the follow-up of patients previously treated for bladder cancer. BMC Urol. 2020 Feb 11; 20(1):12. Koya M, Osborne S, Chemaslé C, Porten S, Schuckman A, Kennedy-Smith A. PMID: 32046687; PMCID: PMC7014779.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    60. Role of Indoleamine-2,3-Dioxygenase Inhibitors in Salvage Therapy for Non-Muscle Invasive Bladder Cancer. Urol Clin North Am. 2020 Feb; 47(1):111-118. Chu CE, Porten SP, Grossfeld GD, Meng MV. PMID: 31757294.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    61. Promotion Disparities in Academic Urology. Urology. 2020 04; 138:16-23. Breyer BN, Butler C, Fang R, Meeks W, Porten SP, North AC, Anger JT. PMID: 31917291.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    62. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials. Clin Cancer Res. 2020 02 15; 26(4):882-891. Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. PMID: 31712383.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCells
    63. Gender differences in oncologic and functional outcomes in patients with bladder cancer undergoing radical cystectomy with urinary diversion. Curr Opin Urol. 2019 09; 29(5):542-547. Sadighian M, Porten S. PMID: 31313715.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    64. Optimizing cystectomy outcomes. Cancer. 2019 10 15; 125(20):3502-3503. Porten SP, Master VA. PMID: 31299088.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    65. Evaluation of Cxbladder and Adjudication of Atypical Cytology and Equivocal Cystoscopy. Eur Urol. 2019 08; 76(2):238-243. Konety B, Shore N, Kader AK, Porten S, Daneshmand S, Lough T, Lotan Y. PMID: 31103391.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    66. Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. Cancer Epidemiol Biomarkers Prev. 2019 08; 28(8):1339-1344. Washington SL, Neuhaus J, Meng MV, Porten SP. PMID: 31092404; PMCID: PMC6679737.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    67. Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors. Eur Urol. 2019 08; 76(2):200-206. Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA. PMID: 31092337.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    68. The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice. Urology. 2019 05; 127:19-23. Washington SL, Porten SP, Quanstrom K, Jin C, Bridge M, Finlayson E, Walter LC, Suskind AM. PMID: 30822479; PMCID: PMC6495603.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    69. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. Clin Genitourin Cancer. 2019 06; 17(3):e461-e471. Balakrishnan AS, Washington SL, Meng MV, Porten SP. PMID: 30799130.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. Epigenetic Alterations in Bladder Cancer. Curr Urol Rep. 2018 Oct 24; 19(12):102. Porten SP. PMID: 30357502.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCells
    71. Unraveling Associations Between Occupation and Bladder Cancer Aggressiveness: Describing the Landscape. Eur Urol Focus. 2018 09; 4(5):731-732. Psutka SP, Porten S. PMID: 30154044.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. Do Women Work Less Than Men in Urology: Data From the American Urological Association Census. Urology. 2018 Aug; 118:71-75. Porten SP, Gaither TW, Greene KL, Baradaran N, Anger JT, Breyer BN. PMID: 29723591.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    73. Integrative analysis of the epigenetic basis of muscle-invasive urothelial carcinoma. Clin Epigenetics. 2018; 10:19. Sanford T, Meng MV, Railkar R, Agarwal PK, Porten SP. PMID: 29456764; PMCID: PMC5809922.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    74. Copy number gains at chr3p25 and chr11p11 are associated with lymph node involvement and survival in muscle-invasive bladder tumors. PLoS One. 2017; 12(11):e0187975. Lindquist KJ, Sanford T, Friedlander TW, Paris PL, Porten SP. PMID: 29140994; PMCID: PMC5687759.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    75. The Cancer of the Bladder Risk Assessment (COBRA) score: Estimating mortality after radical cystectomy. Cancer. 2017 Dec 01; 123(23):4574-4582. Welty CJ, Sanford TH, Wright JL, Carroll PR, Cooperberg MR, Meng MV, Porten SP. PMID: 28881475.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    76. Employing an orthotopic model to study the role of epithelial-mesenchymal transition in bladder cancer metastasis. Oncotarget. 2017 May 23; 8(21):34205-34222. Roth B, Jayaratna I, Sundi D, Cheng T, Melquist J, Choi W, Porten S, Nitti G, Navai N, Wszolek M, Guo C, Czerniak B, McConkey D, Dinney C. PMID: 27494900; PMCID: PMC5470961.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    77. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus. 2018 09; 4(5):720-724. Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. PMID: 28753837.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    78. Development and Validation of Consensus Contouring Guidelines for Adjuvant Radiation Therapy for Bladder Cancer After Radical Cystectomy. Int J Radiat Oncol Biol Phys. 2016 09 01; 96(1):78-86. Baumann BC, Bosch WR, Bahl A, Birtle AJ, Breau RH, Challapalli A, Chang AJ, Choudhury A, Daneshmand S, El-Gayed A, Feldman A, Finkelstein SE, Guzzo TJ, Hilman S, Jani A, Malkowicz SB, Mantz CA, Master V, Mitra AV, Murthy V, Porten SP, Richaud PM, Sargos P, Efstathiou JA, Eapen LJ, Christodouleas JP. PMID: 27511849; PMCID: PMC5207044.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    79. The Efficient and Effective Use of Exfoliative Urinary Markers. Urol Pract. 2016 May; 3(3):195-202. Whitson JM, Porten SP, Hussein AA, Meng MV. PMID: 37592491.
      View in: PubMed   Mentions:    Fields:    
    80. Intravesical chemotherapy in non-muscle-invasive bladder cancer. Indian J Urol. 2015 Oct-Dec; 31(4):297-303. Porten SP, Leapman MS, Greene KL. PMID: 26604440; PMCID: PMC4626913.
      View in: PubMed   Mentions: 16  
    81. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol. 2016 05; 69(5):855-62. McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. PMID: 26343003; PMCID: PMC4775435.
      View in: PubMed   Mentions: 128     Fields:    Translation:HumansCellsCTClinical Trials
    82. Molecular Analysis of Upper Tract and Bladder Urothelial Carcinoma: Results from a Microarray Comparison. PLoS One. 2015; 10(8):e0137141. Sanford T, Porten S, Meng MV. PMID: 26317352; PMCID: PMC4552875.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    83. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90. Hussein AA, Welty CJ, Ameli N, Cowan JE, Leapman M, Porten SP, Shinohara K, Carroll PR. PMID: 25623742.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    84. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. 2014 Sep; 24(5):517-23. Porten SP, Willis D, Kamat AM. PMID: 24921905.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    85. Updated trends in imaging use in men diagnosed with prostate cancer. Prostate Cancer Prostatic Dis. 2014 Sep; 17(3):246-51. Porten SP, Smith A, Odisho AY, Litwin MS, Saigal CS, Carroll PR, Cooperberg MR, Urologic Disease of America Project. PMID: 24819235; PMCID: PMC4266691.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    86. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer. 2014 Jun 15; 120(12):1794-9. Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. PMID: 24633966; PMCID: PMC4440575.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    87. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014 Feb 10; 25(2):152-65. Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CP, McConkey DJ. PMID: 24525232; PMCID: PMC4011497.
      View in: PubMed   Mentions: 801     Fields:    Translation:Humans
    88. Xanthogranulomatous pyelonephritis presenting with a left flank mass. Case Rep Med. 2013; 2013:362194. Zaid UB, Porten SP, Cinman NM, Sanford TH, Breyer BN. PMID: 24367381; PMCID: PMC3866812.
      View in: PubMed   Mentions:
    89. Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer. Eur Urol. 2014 Feb; 65(2):267-9. Kamat AM, Porten S. PMID: 24199712; PMCID: PMC4676267.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    90. Should histologic variants alter definitive treatment of bladder cancer? Curr Opin Urol. 2013 Sep; 23(5):435-43. Willis DL, Porten SP, Kamat AM. PMID: 23880739.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    91. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol. 2014 Jan; 191(1):40-7. Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. PMID: 23911605; PMCID: PMC4158919.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    92. Gunshot wounds to the lower urinary tract: a single-institution experience. J Trauma Acute Care Surg. 2013 Mar; 74(3):725-30; discussion 730-1. Cinman NM, McAninch JW, Porten SP, Myers JB, Blaschko SD, Bagga HS, Breyer BN. PMID: 23425728; PMCID: PMC4122300.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    93. The role of active surveillance in the management of prostate cancer. J Natl Compr Canc Netw. 2013 Feb 01; 11(2):183-7. Fung-Kee-Fung SD, Porten SP, Meng MV, Kuettel M. PMID: 23411385.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    94. Active surveillance: does serial prostate biopsy increase histological inflammation? Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):165-9. Glass AS, Porten SP, Bonham M, Tran TC, Cowan JE, Punnen S, Chan JM, Carroll PR. PMID: 23318528.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    95. High-risk nonmuscle invasive bladder cancer: definition and epidemiology. Curr Opin Urol. 2012 Sep; 22(5):385-9. Porten SP, Cooperberg MR. PMID: 22842681.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    96. Commentary on refractory ischemic priapism. Transl Androl Urol. 2012 Mar; 1(1):61-5. Garcia M, Porten S, Lue TF. PMID: 26813294; PMCID: PMC4713211.
      View in: PubMed   Mentions: 8  
    97. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9. Porten SP, Whitson JM, Cowan JE, Perez N, Shinohara K, Carroll PR. PMID: 21944082.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    98. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. Porten SP, Whitson JM, Cowan JE, Cooperberg MR, Shinohara K, Perez N, Greene KL, Meng MV, Carroll PR. PMID: 21632511.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    99. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. PMID: 21478037.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    100. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. Whitson JM, Porten SP, Hilton JF, Cowan JE, Perez N, Cooperberg MR, Greene KL, Meng MV, Simko JP, Shinohara K, Carroll PR. PMID: 21419438.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansPHPublic Health
    101. The example of CaPSURE: lessons learned from a national disease registry. World J Urol. 2011 Jun; 29(3):265-71. Porten SP, Cooperberg MR, Konety BR, Carroll PR. PMID: 21347810; PMCID: PMC3099175.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    102. Prostate cancer: reducing overtreatment: active surveillance in low-risk disease. Nat Rev Urol. 2011 Mar; 8(3):124-5. Whitson JM, Porten SP, Carroll PR. PMID: 21304508.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    103. The outcomes of perineal urethrostomy with preservation of the dorsal urethral plate and urethral blood supply. Urology. 2011 May; 77(5):1223-7. Myers JB, Porten SP, McAninch JW. PMID: 21215434.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    104. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. Cooperberg MR, Cowan JE, Hilton JF, Reese AC, Zaid HB, Porten SP, Shinohara K, Meng MV, Greene KL, Carroll PR. PMID: 21115873; PMCID: PMC3058278.
      View in: PubMed   Mentions: 95     Fields:    Translation:Humans
    105. Disproportionate presentation of high risk prostate cancer in a safety net health system. J Urol. 2010 Nov; 184(5):1931-6. Porten SP, Richardson DA, Odisho AY, McAninch JW, Carroll PR, Cooperberg MR. PMID: 20846693.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    106. Diabetic kidney stone formers excrete more oxalate and have lower urine pH than nondiabetic stone formers. J Urol. 2010 Jun; 183(6):2244-8. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20400141.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    107. The role of race in determining 24-hour urine composition in white and Asian/Pacific Islander stone formers. J Urol. 2010 Apr; 183(4):1407-11. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20171692.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    108. Hypertension is associated with increased urinary calcium excretion in patients with nephrolithiasis. J Urol. 2010 Feb; 183(2):576-9. Eisner BH, Porten SP, Bechis SK, Stoller ML. PMID: 20018328.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    109. Prevalence and severity of undiagnosed urinary incontinence in women. Am J Med. 2009 Nov; 122(11):1037-42. Wallner LP, Porten S, Meenan RT, O'Keefe Rosetti MC, Calhoun EA, Sarma AV, Clemens JQ. PMID: 19854332; PMCID: PMC2768650.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    110. The independent value of tumour volume in a contemporary cohort of men treated with radical prostatectomy for clinically localized disease. BJU Int. 2010 Feb; 105(4):472-5. Porten SP, Cooperberg MR, Carroll PR. PMID: 19681901; PMCID: PMC2821458.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    111. Diagnosis of female diverticula using magnetic resonance imaging. Adv Urol. 2008; 213516. Porten S, Kielb S. PMID: 18604291; PMCID: PMC2441842.
      View in: PubMed   Mentions: 3  
    112. Office management of pediatric primary nocturnal enuresis: a comparison of physician advised and parent chosen alternative treatment outcomes. J Urol. 2007 Oct; 178(4 Pt 2):1758-61; discussion 1762. Diaz Saldano D, Chaviano AH, Maizels M, Yerkes EB, Cheng EY, Losavio J, Porten SP, Sullivan C, Zebold KF, Hagerty J, Kaplan WE. PMID: 17707433.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    113. Math5 is required for both early retinal neuron differentiation and cell cycle progression. Dev Biol. 2006 Jul 15; 295(2):764-78. Le TT, Wroblewski E, Patel S, Riesenberg AN, Brown NL. PMID: 16690048.
      View in: PubMed   Mentions: 62     Fields:    Translation:AnimalsCells
    114. Math5 is required for retinal ganglion cell and optic nerve formation. Development. 2001 Jul; 128(13):2497-508. Brown NL, Patel S, Brzezinski J, Glaser T. PMID: 11493566; PMCID: PMC1480839.
      View in: PubMed   Mentions: 241     Fields:    Translation:AnimalsCells
    Sima's Networks
    Concepts (337)
    Derived automatically from this person's publications.
    _
    Co-Authors (90)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _